Uebel, A.; Kewitz-Hempel, S.; Willscher, E.; Gebhardt, K.; Sunderkötter, C.; Gerloff, D.
Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. Int. J. Mol. Sci. 2023, 24, 1963.
https://doi.org/10.3390/ijms24031963
AMA Style
Uebel A, Kewitz-Hempel S, Willscher E, Gebhardt K, Sunderkötter C, Gerloff D.
Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. International Journal of Molecular Sciences. 2023; 24(3):1963.
https://doi.org/10.3390/ijms24031963
Chicago/Turabian Style
Uebel, Anne, Stefanie Kewitz-Hempel, Edith Willscher, Kathleen Gebhardt, Cord Sunderkötter, and Dennis Gerloff.
2023. "Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma" International Journal of Molecular Sciences 24, no. 3: 1963.
https://doi.org/10.3390/ijms24031963
APA Style
Uebel, A., Kewitz-Hempel, S., Willscher, E., Gebhardt, K., Sunderkötter, C., & Gerloff, D.
(2023). Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. International Journal of Molecular Sciences, 24(3), 1963.
https://doi.org/10.3390/ijms24031963